by Sue Robbins | Nov 23, 2020 | Migraine
Therapy options for patients with migraines have expanded over the past couple of years, with several new drug classes specific to the disorder. Leading migraine experts discuss how they decide to choose one therapy over another. Treatment options for migraine have...
by Sue Robbins | Nov 22, 2020 | Migraine
In 2018 the FDA approved three new medications to treat migraine.1 These medications are known by the brand names Aimovig, Emgality, and Ajovy. All three medications are in a class called calcitonin gene-related peptide inhibitors (CGRPs). CGRPs developed to treat...
by Sue Robbins | Nov 18, 2020 | Miscellaneous
This winter the pandemic is expected to intensify the depression experienced by many people with the syndrome known as seasonal affective disorder, or SAD. We hadn’t yet switched back to standard time, with its shortened hours of afternoon daylight, when I began to...
by Sue Robbins | Nov 17, 2020 | Migraine
Nearly 80% of people taking a new class of medication to prevent migraine say their migraine headaches are “better” since they started taking the drugs, according to a survey conducted by Eli Lilly. Calcitonin gene-related peptide (CGRP) inhibitors prevent migraines...
by Sue Robbins | Nov 15, 2020 | Wellness
Amid a global pandemic, climate change, racial unrest and a 24/7 news cycle, self-care is no longer a luxury — it’s a necessity. Collective stress and anxiety have surged in 2020. Almost 50% percent of Americans between the ages of 18 and 29 said they’ve...
